A Flight to Quality Is Reshaping ABA Dealmaking in 2026

Deals Are Back, but Different

Autism services dealmaking has come back to life, and it is pickier than it has ever been. After the slow years of 2022 and 2023, transaction volume rebounded through 2025 and into 2026, with private equity returning to a sector it had cooled on. The intellectual and developmental disabilities space set a record in 2025 with 31 deals, edging out the 30 logged in 2021, according to the M&A advisory firm The Braff Group, and autism dealmaking followed close behind. The fundamentals that drew investors in the first place, high unmet demand, an outpatient model, and a still-fragmented provider base, have not changed.

The recent run of transactions shows the pattern. In May 2026, Gryphon Investors-backed LEARN Behavioral bought Little Leaves Behavioral Services, an 18-center early-intervention provider across Maryland, Virginia, and Florida, from FullBloom. In February, the Goldman Sachs Alternatives-backed Center for Social Dynamics acquired New Mexico’s Behavior Change Institute, and in January, Renovus Capital’s Behavioral Framework added Autism ETC, a 5-clinic provider across Tennessee and Arizona. Buyers are active again. They are also far more selective about what they will touch.

The Little Leaves deal is instructive about what now trades. The division runs 18 center-based programs for children ages one to six in a preschool-like early-intervention model across Maryland, Virginia, and Florida, including two Virginia sites in Chantilly and Tysons Corner opened in late 2025. Its closing on May 11 put Florida on LEARN’s map for the first time and moved the ABA business from one private-equity-backed parent to another, pulling FullBloom, an American Securities company, out of direct ABA delivery and toward K-12 education and school-based mental health. It was a clean, reputable early-intervention group changing hands, not a distressed roll-up, which is the kind of asset the 2026 market rewards.

What Sank the First Wave

That selectivity is a direct lesson from the last cycle. The pullback in autism dealmaking from 2020 to 2023 was not only about interest rates. The sector was also working off what The Braff Group called a hangover from the failure of several high-profile consolidators, roll-ups that had grown fast, leaned hard on Medicaid, and stumbled on quality and compliance. The bankruptcy of the Center for Autism and Related Disorders, once the largest ABA provider in the country, under Blackstone ownership became the cautionary tale of the era.

The scrutiny has only intensified since. A study published in JAMA Pediatrics in January 2026, by researchers at Brown University, counted 574 private-equity-owned autism therapy centers across 42 states as of 2024, nearly 80 percent of them acquired between 2018 and 2022. The researchers raised a pointed concern that financial owners might push children toward more billable therapy hours than is clinically appropriate, with most of those children insured by Medicaid. That is precisely the behavior today’s buyers say they are screening to avoid, because it is what regulators are now screening for too.

Growth bought with Medicaid hours and thin documentation did not survive the first wave. Buyers remember.

The Red Flags Buyers Now Screen

Diligence in 2026 looks different. Buyers and their advisers describe a review that runs well past the income statement to clinical quality, staffing stability, payer mix, documentation, and culture. The warning signs that send acquirers to the next target are consistent. Over-reliance on Medicaid in states facing rate cuts. Billing that over-indexes on authorized therapy hours. High clinician turnover in a market already short on board-certified behavior analysts. Documentation that will not survive an audit. And a growth-at-all-costs history, the same trait that defined the platforms that failed.

Several of those risks are no longer hypothetical. Medicaid pressure is concrete, from rate disputes to the provider revalidation purge in Minnesota and the managed-care shift that has squeezed margins in Florida. Documentation and compliance failures now invite fraud enforcement. The practical effect is that due diligence has become as much a character test as a financial one: a clinic’s online staff and family reviews, its turnover, and its audit history are weighed alongside its earnings. A seller cannot paper over culture or clinical integrity in a data room.

Florida is the clearest live example of why payer mix has moved to the center of diligence. The state transitioned behavior-analysis services into Medicaid managed care in early 2025, a shift that compressed margins for some operators as authorizations and rates passed through managed-care intermediaries. A platform whose revenue leans heavily on a single state Medicaid program undergoing that kind of structural change carries a risk a buyer can model but cannot easily fix after closing. The buyers screening hardest are the ones who lived through the last cycle’s write-downs and have no appetite to repeat them.

Quality Has a Price

The result is a widening gap. Well-run autism platforms, the ones with strong clinical leadership, diversified payers, and clean operations, still command premium prices: advisers peg the best assets at mid-to-high-teens multiples of earnings, and even small high-quality providers draw competitive interest. The broader market has settled much lower, into the high single digits, roughly 6 to 8 times earnings. The spread between those two numbers is the flight to quality made literal.

The buyer pool has also broadened. Scaled strategic operators, not just financial sponsors, are tucking in quality regional providers: LEARN folded in Indiana’s Cornerstone Autism Center and Wisconsin’s KGH Autism Services earlier in 2026, and the Little Leaves purchase moved a respected early-intervention group from one platform onto a larger one. Acquirers increasingly prize clinical quality, stable staffing, and technology adoption, the markers of an operation that can prove its outcomes. As one M&A adviser noted, the breadth of the buyer pool is itself a positive signal for sellers, provided the asset can withstand the scrutiny.

That breadth is visible in the deal record. Within the first half of 2026, LEARN alone integrated Indiana’s Cornerstone Autism Center under its BACA brand and added Wisconsin’s KGH Autism Services before the Little Leaves purchase, three tuck-ins of established regional providers in a single stretch. Advisers tracking the market describe the pattern as strategic operators, not only financial sponsors, competing for clinically credible groups with local payer relationships. For a strong seller, more bidder types means more tension in a process; for a weak one, a broader pool changes little, because the additional buyers are looking for the same markers of quality.

The strongest platforms still fetch high-teens multiples. The rest wait for a buyer, or a markdown.

Accreditation Becomes the Floor

Quality is also becoming a regulatory requirement, not just a buyer preference. Massachusetts, after its attorney general and inspector general questioned quality control at ABA clinics, became the first state to require accreditation for ABA providers that bill its Medicaid program. Center-based providers must be accredited by a nationally recognized ABA accreditor by January 1, 2027, and providers in other settings by January 1, 2028. Payers including Point32Health, the parent of Harvard Pilgrim and Tufts plans, have aligned their contracting to the same deadlines. The nonprofit Autism Commission on Quality, backed by the Council of Autism Service Providers has seen a rush of interest.

The Massachusetts rule did not emerge in a vacuum. It followed a 2024 review by the state’s Office of the Inspector General that found managed-care entities contracted with MassHealth had not employed robust program-integrity measures to ensure children received properly supervised treatment. The accreditation mandate was the state’s structural answer: rather than police quality only through retrospective billing audits, it pushed providers toward independent evaluation of supervision practices, treatment planning, and staff competency. Demand for ABA has kept climbing through the same period, with industry data pointing to roughly 40 percent growth in service volume between 2022 and 2024, which is part of why regulators and payers have grown more insistent that growth be matched by verifiable quality.

For owners weighing a sale, the message from buyers and regulators now points the same direction. The providers that clear diligence and command the best multiples are the ones that invested early in clinical quality, stable staffing, diversified payers, and the documentation to prove it. The next test is concrete and dated: by January 1, 2027, every center-based ABA provider in the Massachusetts Medicaid program must carry an outside accreditation, and the states watching Massachusetts will decide whether quality becomes the price of admission everywhere else.

AT A GLANCE

SOURCES & REFERENCES